Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2013 April;61(2) > Minerva Cardioangiologica 2013 April;61(2):155-63

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

  INTERVENTIONAL INNOVATION NOVEL THERAPIES AND THE BEST NEW DEVICE CONCEPT FOR 2013 

Minerva Cardioangiologica 2013 April;61(2):155-63

Copyright © 2013 EDIZIONI MINERVA MEDICA

language: English

Innovations and novel technologies in TAVI. Second generation transcatheter heart valves

Sinning J. M., Werner N., Vasa-Nicotera M., Ghanem A., Hammerstingl C., Grube E., Nickenig G.

Herzzentrum Bonn, Medizinische Klinik und Poliklinik II,, Universitätsklinikum Bonn, Germany


PDF


Transcatheter aortic valve implantation (TAVI) is the new standard-of-care for inoperable patients with superior outcome compared to conservative management including balloon valvuloplasty. In high-risk patients, TAVI has shown non-inferiority compared with surgical aortic valve replacement. Although data from national multi-centre registries are very encouraging and use of TAVI in intermediate risk patients has been discussed, it is of note that the commercially available and currently used transcatheter heart valves (THV) have not yet been assessed by randomized clinical trials in those patients. New technology advances promise to simplify TAVI and to improve outcome by reducing the rate of TAVI-specific issues such as paravalvular aortic regurgitation (PAR), annular rupture, and conduction disturbances. A reduction in the incidence and severity of PAR represents an obvious target for technical improvements in the design of upcoming “next generation” THVs and of implantation techniques including repositioning/recapturing features, paravalvular sealing techniques, and precise peri-interventional imaging modalities.

top of page